Hester Biosciences (BOM:524669) Cyclically Adjusted Revenue per Share: ₹346.78 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524669 Hester Biosciences Ltd BOM:524669
73 GF Score
Price ₹2,385.90
GF Value ₹1,874.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hester Biosciences Cyclically Adjusted Revenue per Share?

Hester Biosciences BOM:524669 -0.81% 73 Cyclically Adjusted Revenue per Share is ₹346.78 as of Jun. 2026. GuruFocus rates BOM:524669 with a GF Score™ of 73/100 and a GF Value™ of ₹1,874.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hester Biosciences's adjusted revenue per share for the three months ended in Jun. 2026 was ₹90.566. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹346.78 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Hester Biosciences's average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-23), Hester Biosciences's current stock price is ₹2385.90. Hester Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹346.78. Hester Biosciences's Cyclically Adjusted PS Ratio of today is 6.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hester Biosciences was 10.81. The lowest was 4.07. And the median was 5.97.


Hester Biosciences  (BOM:524669) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hester Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2385.90/346.78
=6.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hester Biosciences was 10.81. The lowest was 4.07. And the median was 5.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hester Biosciences Cyclically Adjusted Revenue per Share Related Terms


Hester Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hester Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hester Biosciences Cyclically Adjusted Revenue per Share Chart

Hester Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 307.88 336.49

Hester Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 315.33 320.65 324.43 336.49 346.78

BOM:524669 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hester Biosciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hester Biosciences's Cyclically Adjusted PS Ratio falls into.


BOM:524669
73GF Score
Hester Biosciences Ltd BOM:524669
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hester Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hester Biosciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=90.566/167.3573*167.3573
=90.566

Current CPI (Jun. 2026) = 167.3573.

Hester Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 21.983 83.774 43.916
201303 20.011 85.687 39.084
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 46.794 111.317 70.352
201809 50.280 115.142 73.081
201812 53.758 115.142 78.137
201903 58.486 118.202 82.808
201906 52.613 120.880 72.842
201909 51.955 123.175 70.591
201912 59.589 126.235 79.001
202003 51.275 124.705 68.812
202006 46.847 127.000 61.734
202009 62.747 130.118 80.705
202012 66.879 130.889 85.513
202103 75.438 131.771 95.811
202106 70.749 134.084 88.305
202109 77.151 135.847 95.047
202112 65.463 138.161 79.297
202203 66.379 138.822 80.024
202206 53.532 142.347 62.937
202209 81.882 144.661 94.729
202212 95.738 145.763 109.921
202303 76.782 146.865 87.496
202306 118.098 150.280 131.518
202309 82.820 151.492 91.493
202312 79.524 152.924 87.029
202403 79.741 153.035 87.204
202406 114.260 155.789 122.745
202409 100.652 157.882 106.693
202412 72.698 158.323 76.846
202503 115.501 157.552 122.689
202506 103.987 159.755 108.935
202509 82.763 162.289 85.348
202512 96.624 163.281 99.036
202603 121.833 164.272 124.121
202606 90.566 167.357 90.566

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹346.78 mean?
Hester Biosciences (BOM:524669) has a Cyclically Adjusted Revenue per Share of ₹346.78 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hester Biosciences and its competitors.
Is Hester Biosciences' Cyclically Adjusted Revenue per Share too high?
Hester Biosciences' current Cyclically Adjusted Revenue per Share is ₹346.78. Overall, Hester Biosciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Cyclically Adjusted Revenue per Share compare to ZTS?
Hester Biosciences' Cyclically Adjusted Revenue per Share of ₹346.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hester Biosciences and its competitors. Hester Biosciences's current Cyclically Adjusted Revenue per Share is ₹346.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,874.22, compared to a current price of ₹2,385.90 — trading 27.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹346.78. Hester Biosciences' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Cyclically Adjusted Revenue per Share is ₹346.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hester Biosciences (BOM:524669) Overvalued in 2026?

Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued. The current stock price of ₹2,385.90 is trading 27.3% above its estimated GF Value™ of ₹1,874.22. GuruFocus considers Hester Biosciences to be Modestly Overvalued.

Key valuation signals for BOM:524669:

  • Cyclically Adjusted Revenue per Share: ₹346.78
  • GF Value™: ₹1,874.22 vs. price of ₹2,385.90 (27.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hester Biosciences Business Description

Other Exchanges HESTERBIO:India
Address Village Meda - Adraj, Taluka Kadi, District Mehsana, Mehsana, GJ, IND, 384441
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
73GF Score

Get the complete analysis for BOM:524669

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,385.90
Price
₹1,874.22
GF Value